Publications by authors named "Kuhan Pushparatnam"
Article Synopsis
- Importance of PPIE
- : Patient and public involvement and engagement (PPIE) are crucial for designing effective trials, as they enhance participant experience and overall delivery.
- EJS ACT-PD Initiative
- : The UK consortium aims to integrate PPIE into all aspects of a clinical trial focused on disease-modifying therapies for Parkinson's Disease (PD).
- Evaluation and Impact
- : A working group involving patients and care partners is developing processes to evaluate PPIE effectiveness, using various research methods to assess the quality and impact of their involvement on trial outcomes.
Background: Clinical trials of disease-modifying therapies in PD require valid and responsive primary outcome measures that are relevant to patients.
Objectives: The objective is to select a patient-centered primary outcome measure for disease-modification trials over three or more years.
Methods: Experts in Parkinson's disease (PD), statistics, and health economics and patient and public involvement and engagement (PPIE) representatives reviewed and discussed potential outcome measures.
Background: Multi-arm, multi-stage (MAMS) platform trials can accelerate the identification of disease-modifying treatments for Parkinson's disease (PD) but there is no current consensus on the optimal outcome measures (OM) for this approach.
Objective: To provide an up-to-date inventory of OM for disease-modifying PD trials, and a framework for future selection of OM for such trials.
Methods: As part of the Edmond J Safra Accelerating Clinical Trials in Parkinson Disease (EJS ACT-PD) initiative, an expert group with Patient and Public Involvement and Engagement (PPIE) representatives' input reviewed and evaluated available evidence on OM for potential use in trials to delay progression of PD.